{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:42:06Z","timestamp":1792582926278,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The processes of clot formation and clot dissolution with fibrinolysis underpin the pathophysiological mechanisms of acute ischaemic stroke (AIS) and its treatment. Detailed understanding of the modulation of this system is required to develop effective and safe stroke therapeutics. Clot formation occurs with the interaction of the coagulation cascade, along with platelets and fibrin meshwork. Conversely, fibrinolysis involves the serine protease plasmin, its zymogen, plasminogen and its enzymatic conversion by tissue plasminogen activator. The regulators and inhibitors that modulate the interactions in clot formation and fibrinolysis can be potential targets for new and emerging stroke therapies. The aim of this narrative review is to help inform stroke clinicians and researchers about the role of the fibrinolytic system and its inhibitors in AIS and the potential for new therapeutic targets. We outline the processes involved in clot formation and dissolution, the role of endogenous inhibitors of the fibrinolytic system, followed by potential therapeutic targets including tissue plasminogen activators as well as novel therapies and adjuncts. Better understanding of these processes will provide insight into the variable response to current stroke fibrinolytics amongst AIS patients and help to develop new and improved AIS therapeutics in future.<\/jats:p>","DOI":"10.1007\/s12975-026-01502-0","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:48:00Z","timestamp":1791856080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Ischaemic Stroke: Therapeutic Targets and Key Modulators of the Fibrinolytic System and Clot Formation"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-1803","authenticated-orcid":false,"given":"Oshi","family":"Swarup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-3101","authenticated-orcid":false,"given":"Anna H.","family":"Balabanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-6907","authenticated-orcid":false,"given":"Geoffrey C.","family":"Cloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-3892","authenticated-orcid":false,"given":"Robert L.","family":"Medcalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1502_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/CBO9781316095805.003","volume-title":"Caplan\u2019s Stroke: A Clinical Approach","author":"LR Caplan","year":"2016","unstructured":"Caplan LR, Liebeskind DS. Pathology, anatomy, and pathophysiology of stroke. In: Caplan LR, editor. Caplan\u2019s Stroke: A Clinical Approach. 5 ed. Cambridge: Cambridge University Press; 2016. pp. 19\u201354.","edition":"5"},{"key":"1502_CR2","doi-asserted-by":"crossref","unstructured":"Jolugbo P, Ariens RAS. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke. Stroke.52(3):1131\u201342.","DOI":"10.1161\/STROKEAHA.120.032810"},{"issue":"10","key":"1502_CR3","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1182\/blood-2013-08-523860","volume":"123","author":"DB Cines","year":"2014","unstructured":"Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI, et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood. 2014;123(10):1596\u2013603.","journal-title":"Blood"},{"issue":"2","key":"1502_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/STROKEAHA.111.628867","volume":"43","author":"SF De Meyer","year":"2012","unstructured":"De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012;43(2):599\u2013606.","journal-title":"Stroke"},{"issue":"3","key":"1502_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood.V100.3.743","volume":"100","author":"RA Ariens","year":"2002","unstructured":"Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100(3):743\u201354.","journal-title":"Blood"},{"issue":"2","key":"1502_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.24993","volume":"82","author":"E Laridan","year":"2017","unstructured":"Laridan E, Denorme F, Desender L, Francois O, Andersson T, Deckmyn H, et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol. 2017;82(2):223\u201332.","journal-title":"Ann Neurol"},{"issue":"3","key":"1502_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1161\/01.CIR.96.3.761","volume":"96","author":"WL Chandler","year":"1997","unstructured":"Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of Tissue Plasminogen Activator (TPA) and TPA\/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex. Circulation. 1997;96(3):761\u20138.","journal-title":"Circulation"},{"issue":"9","key":"1502_CR8","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood.V80.9.2269.2269","volume":"80","author":"IM Lang","year":"1992","unstructured":"Lang IM, Marsh JJ, Moser KM, Schleef RR. Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets. Blood. 1992;80(9):2269\u201374.","journal-title":"Blood"},{"issue":"6357","key":"1502_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/355270a0","volume":"355","author":"J Mottonen","year":"1992","unstructured":"Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 1992;355(6357):270\u20133.","journal-title":"Nature"},{"issue":"4","key":"1502_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1538-7836.2007.02430.x","volume":"5","author":"NJ Mutch","year":"2007","unstructured":"Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA, TAFIa. PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost. 2007;5(4):812\u20137.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1502_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1160\/TH09-10-0682","volume":"103","author":"DH Kozian","year":"2010","unstructured":"Kozian DH, Lorenz M, Marz W, Cousin E, Mace S, Deleuze JF. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb Haemostasis. 2010;103(5):976\u201383.","journal-title":"Thromb Haemostasis"},{"issue":"10","key":"1502_CR12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/j.1538-7836.2005.01484.x","volume":"3","author":"FW Leebeek","year":"2005","unstructured":"Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemostasis. 2005;3(10):2211\u20138.","journal-title":"J Thromb Haemostasis"},{"issue":"2","key":"1502_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1055\/s-0038-1651570","volume":"69","author":"M Levi","year":"1993","unstructured":"Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost. 1993;69(2):141\u20136.","journal-title":"Thromb Haemost"},{"key":"1502_CR14","doi-asserted-by":"crossref","unstructured":"Bhambri A, Adapa AR, Liu Y, Boeckh-Behrens T, Prochazka V, Hernandez-Fernandez F et al. Thrombus histology as it relates to mechanical thrombectomy: a meta-analysis and systematic review. Neurosurgery.89(6):1122-31.","DOI":"10.1093\/neuros\/nyab366"},{"key":"1502_CR15","doi-asserted-by":"crossref","unstructured":"Choi MH, Park GH, Lee JS, Lee SE, Lee SJ, Kim JH et al. Erythrocyte fraction within retrieved thrombi contributes to thrombolytic response in acute ischemic stroke. Stroke.49(3):652-9.","DOI":"10.1161\/STROKEAHA.117.019138"},{"key":"1502_CR16","doi-asserted-by":"crossref","unstructured":"Boeckh-Behrens T, Kleine JF, Zimmer C, Neff F, Scheipl F, Pelisek J et al. Thrombus histology suggests cardioembolic cause in cryptogenic stroke. Stroke.47(7):1864\u201371.","DOI":"10.1161\/STROKEAHA.116.013105"},{"key":"1502_CR17","doi-asserted-by":"crossref","unstructured":"Sporns PB, Hanning U, Schwindt W, Velasco A, Minnerup J, Zoubi T et al. Ischemic stroke: what does the histological composition tell us about the origin of the thrombus? Stroke.48(8):2206\u201310.","DOI":"10.1161\/STROKEAHA.117.016590"},{"issue":"9","key":"1502_CR18","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1161\/STROKEAHA.120.029134","volume":"51","author":"L Di Meglio","year":"2020","unstructured":"Di Meglio L, Desilles JP, Solonomenjanahary M, Labreuche J, Ollivier V, Dupont S, et al. DNA Content in Ischemic Stroke Thrombi Can Help Identify Cardioembolic Strokes Among Strokes of Undetermined Cause. Stroke. 2020;51(9):2810\u20136.","journal-title":"Stroke"},{"issue":"8","key":"1502_CR19","first-page":"e316","volume":"57","author":"S Prabhakaran","year":"2026","unstructured":"Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2026;57(8):e316\u2013436.","journal-title":"Stroke"},{"issue":"10","key":"1502_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM198403083101001","volume":"310","author":"F Van de Werf","year":"1984","unstructured":"Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984;310(10):609\u201313.","journal-title":"N Engl J Med"},{"issue":"24","key":"1502_CR21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"National Institute of Neurological","year":"1995","unstructured":"National Institute of Neurological. Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"1502_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/pharmaceutics15030797","volume":"15","author":"Y Yang","year":"2023","unstructured":"Yang Y, Gu B, Xu XY. In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke. Pharmaceutics. 2023;15(3):28.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1502_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1747493017733935","volume":"13","author":"BC Campbell","year":"2018","unstructured":"Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Yan B, et al. Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study. Int J Stroke. 2018;13(3):328\u201334.","journal-title":"Int J Stroke"},{"issue":"9","key":"1502_CR24","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","volume":"91","author":"BA Keyt","year":"1994","unstructured":"Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91(9):3670\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"1502_CR25","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1182\/bloodadvances.2026020921","volume":"10","author":"Z Liu","year":"2026","unstructured":"Liu Z, Tippett I, McCutcheon FM, Keragala CB, McDonald A, Sharma G, et al. Tenecteplase (TNK) and other TNK formulations lose PAI-1 resistance in their two-chain form: comparison with alteplase. Blood Adv. 2026;10(19):6626\u201336.","journal-title":"Blood Adv"},{"issue":"15","key":"1502_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","volume":"41","author":"P Tanswell","year":"2002","unstructured":"Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229\u201345.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1502_CR27","doi-asserted-by":"publisher","first-page":"e0260796","DOI":"10.1371\/journal.pone.0260796","volume":"16","author":"S Izadi","year":"2021","unstructured":"Izadi S, Jalali Javaran M, Rashidi Monfared S, Castilho A. Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. PLoS ONE [Electronic Resource]. 2021;16(11):e0260796.","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"17","key":"1502_CR28","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","volume":"378","author":"BCV Campbell","year":"2018","unstructured":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018;378(17):1573\u201382.","journal-title":"N Engl J Med"},{"issue":"5","key":"1502_CR29","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00415-024-12243-1","volume":"271","author":"Y Ma","year":"2024","unstructured":"Ma Y, Xiang H, Busse JW, Yao M, Guo J, Ge L, et al. Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies. J Neurol. 2024;271(5):2309\u201323.","journal-title":"J Neurol"},{"issue":"24","key":"1502_CR30","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","volume":"390","author":"S Li","year":"2024","unstructured":"Li S, Gu HQ, Li H, Wang X, Jin A, Guo S, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med. 2024;390(24):2264\u201373.","journal-title":"N Engl J Med"},{"issue":"9","key":"1502_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1474-4422(24)00318-1","volume":"23","author":"V Yogendrakumar","year":"2024","unstructured":"Yogendrakumar V, Lin L, Medcalf RL, Parsons MW. Improving thrombolysis efficiency for acute ischaemic stroke. Lancet Neurol. 2024;23(9):853\u20135.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1502_CR32","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1161\/STROKEAHA.116.013715","volume":"47","author":"R von Kummer","year":"2016","unstructured":"von Kummer R, Mori E, Truelsen T, Jensen JS, Gronning BA, Fiebach JB, et al. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke. 2016;47(12):2880\u20137.","journal-title":"Stroke"},{"issue":"6","key":"1502_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(15)00047-2","volume":"14","author":"GW Albers","year":"2015","unstructured":"Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gronning BA, et al. Safety and efficacy of desmoteplase given 3\u20139\u00a0h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575\u201384.","journal-title":"Lancet Neurol"},{"issue":"19","key":"1502_CR34","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","volume":"380","author":"H Ma","year":"2019","unstructured":"Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019;380(19):1795\u2013803.","journal-title":"N Engl J Med"},{"issue":"8","key":"1502_CR35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMoa2310392","volume":"390","author":"GW Albers","year":"2024","unstructured":"Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. N Engl J Med. 2024;390(8):701\u201311.","journal-title":"N Engl J Med"},{"issue":"2","key":"1502_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jamaneurol.2020.4123","volume":"78","author":"BCV Campbell","year":"2021","unstructured":"Campbell BCV, Ma H, Parsons MW, Churilov L, Yassi N, Kleinig TJ, et al. Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials. JAMA Neurol. 2021;78(2):236\u201340.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1502_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","volume":"391","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, et al. Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy. N Engl J Med. 2024;391(3):203\u201312.","journal-title":"N Engl J Med"},{"key":"1502_CR38","doi-asserted-by":"crossref","unstructured":"Furlan AJ, Abou-Chebl A. The role of recombinant pro-urokinase (r-pro-UK) and intra-arterial thrombolysis in acute ischaemic stroke: the PROACT trials. Prolyse in Acute Cerebral Thromboembolism. Curr Med Res Opin.18 Suppl 2:s44\u20137.","DOI":"10.1185\/030079902125000723"},{"issue":"1","key":"1502_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","volume":"24","author":"S Li","year":"2025","unstructured":"Li S, Gu H-Q, Feng B, Li H, Wang X, Dong Q, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4\u00b75\u00a0h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. Lancet Neurol. 2025;24(1):33\u201341.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1502_CR40","doi-asserted-by":"publisher","first-page":"e2325415","DOI":"10.1001\/jamanetworkopen.2023.25415","volume":"6","author":"H Song","year":"2023","unstructured":"Song H, Wang Y, Ma Q, Feng W, Liu R, Lv X, et al. Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2023;6(7):e2325415\u2013e.","journal-title":"JAMA Netw Open"},{"key":"1502_CR41","doi-asserted-by":"crossref","unstructured":"Hashmi TM, Shafiq A, Zia R, Ashraf H, Burhan M, Ahmed M et al. Recombinant human pro-urokinase vs. alteplase within 4.5 hours of acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 2025;34(8).","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108392"},{"issue":"2","key":"1502_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/STROKEAHA.125.051115","volume":"57","author":"NA Shamalov","year":"2026","unstructured":"Shamalov NA, Martynov MY, Yarovaya EB, Chefranova ZY, Kutsenko VA, Semenov AM, et al. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2026;57(2):394\u2013403.","journal-title":"Stroke"},{"issue":"9","key":"1502_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","volume":"20","author":"EI Gusev","year":"2021","unstructured":"Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4\u00b75\u00a0h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721\u20138.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1502_CR44","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1161\/STROKEAHA.124.048464","volume":"55","author":"K Niizuma","year":"2024","unstructured":"Niizuma K, Nishimura N, Hasegawa K, Moritoyo T, Kudo K, Bell J, et al. Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. Stroke. 2024;55(12):2786\u201394.","journal-title":"Stroke"},{"issue":"10","key":"1502_CR45","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.2018.12498","volume":"320","author":"BK Menon","year":"2018","unstructured":"Menon BK, Al-Ajlan FS, Najm M, Puig J, Castellanos M, Dowlatshahi D, et al. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke. JAMA. 2018;320(10):1017\u201326.","journal-title":"JAMA"},{"issue":"9958","key":"1502_CR46","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","volume":"384","author":"J Emberson","year":"2014","unstructured":"Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929\u201335.","journal-title":"Lancet"},{"key":"1502_CR47","doi-asserted-by":"publisher","first-page":"946367","DOI":"10.3389\/fmedt.2022.946367","volume":"4","author":"JST Liu","year":"2022","unstructured":"Liu JST, Ding Y, Schoenwaelder S, Liu X. Improving treatment for acute ischemic stroke-Clot busting innovation in the pipeline. Front Med Technol. 2022;4:946367.","journal-title":"Front Med Technol"},{"issue":"10329","key":"1502_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(22)00014-9","volume":"399","author":"W van der Steen","year":"2022","unstructured":"van der Steen W, van de Graaf RA, Chalos V, Lingsma HF, van Doormaal PJ, Coutinho JM, et al. Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. Lancet. 2022;399(10329):1059\u201369.","journal-title":"Lancet"},{"issue":"3","key":"1502_CR49","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","volume":"43","author":"AD Barreto","year":"2012","unstructured":"Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43(3):770\u20135.","journal-title":"Stroke"},{"issue":"6","key":"1502_CR50","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","volume":"48","author":"AD Barreto","year":"2017","unstructured":"Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, et al. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017;48(6):1608\u201316.","journal-title":"Stroke"},{"issue":"9843","key":"1502_CR51","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(12)60949-0","volume":"380","author":"SM Zinkstok","year":"2012","unstructured":"Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380(9843):731\u20137.","journal-title":"Lancet"},{"issue":"5","key":"1502_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/STROKEAHA.125.052935","volume":"57","author":"M K\u00f6hrmann","year":"2026","unstructured":"K\u00f6hrmann M, Berrouschot J, Serena J, Bornstein NM, Iversen HK, Kalladka D, et al. Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke\u2014ACTISAVE: A Prospective, Randomized, Double-Blind Study. Stroke. 2026;57(5):1116\u201325.","journal-title":"Stroke"},{"issue":"Suppl 2","key":"1502_CR53","first-page":"A36","volume":"16","author":"M K\u00f6hrmann","year":"2024","unstructured":"K\u00f6hrmann M, Toledano E, Pl\u00e9tan Y, Comenducci A, Meilhoc A, Binay S, et al. P024\u2005ACTISAVE study: efficacy and safety of glenzocimab on top of thrombolysis and mechanical thrombectomy. J NeuroInterventional Surg. 2024;16(Suppl 2):A36\u2013A.","journal-title":"J NeuroInterventional Surg"},{"key":"1502_CR54","doi-asserted-by":"crossref","unstructured":"Mazighi M, Lambert J, Gory B, Seners P, Calvi\u00e8re L, Cho TH et al. Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study. J Neurointerv Surg. 2025.","DOI":"10.1136\/jnis-2025-023606"},{"issue":"6","key":"1502_CR55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jama.2022.12584","volume":"328","author":"RBT Investigators","year":"2022","unstructured":"Investigators RBT. Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial. JAMA. 2022;328(6):543\u201353.","journal-title":"JAMA"},{"issue":"1","key":"1502_CR56","doi-asserted-by":"publisher","first-page":"107494","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107494","volume":"33","author":"H Xie","year":"2024","unstructured":"Xie H, Chen Y, Ge W, Xu X, Liu C, Lan Z, et al. Does Endovascular Thrombectomy(ET) plus tirofiban benefit stroke patients: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2024;33(1):107494.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1502_CR57","doi-asserted-by":"crossref","unstructured":"Spina E, Spiezia AL, Pia FD, de Mase A, Maurea C, Servillo G et al. Efficacy and safety of early intravenous administration of tirofiban after thrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2026.","DOI":"10.1007\/s11239-026-03273-9"},{"issue":"4","key":"1502_CR58","doi-asserted-by":"publisher","first-page":"9857","DOI":"10.1097\/JS9.0000000000004601","volume":"112","author":"R Ji","year":"2026","unstructured":"Ji R, Li G, Fan S, Yue C, Guo C, Wan J, et al. Efficacy and safety of adjunctive tirofiban administration in anterior large vessel occlusion due to large artery atherosclerosis: an individual patient data pooled analysis of two randomized clinical trials. Int J Surg. 2026;112(4):9857\u201366.","journal-title":"Int J Surg"},{"issue":"4","key":"1502_CR59","doi-asserted-by":"publisher","first-page":"e255308","DOI":"10.1001\/jamanetworkopen.2025.5308","volume":"8","author":"L Lin","year":"2025","unstructured":"Lin L, Liu F, Yi T, Zhu Y, Yang J, Zhao Y, et al. Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy: The OPTIMISTIC Randomized Clinical Trial. JAMA Netw Open. 2025;8(4):e255308.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1502_CR60","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2503678","volume":"393","author":"C Tao","year":"2025","unstructured":"Tao C, Liu T, Cui T, Liu J, Li Z, Ren Y, et al. Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. N Engl J Med. 2025;393(12):1191\u2013201.","journal-title":"N Engl J Med"},{"key":"1502_CR61","unstructured":"Investigators ITAftI. Intravenous tirofiban after tenecteplase in acute ischemic stroke: the INSTANT randomized clinical trial. JAMA. 2026."},{"issue":"9","key":"1502_CR62","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2314779","volume":"391","author":"O Adeoye","year":"2024","unstructured":"Adeoye O, Broderick J, Derdeyn CP, Grotta JC, Barsan W, Bentho O, et al. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. N Engl J Med. 2024;391(9):810\u201320.","journal-title":"N Engl J Med"},{"issue":"18","key":"1502_CR63","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","volume":"123","author":"K Martinod","year":"2014","unstructured":"Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123(18):2768\u201376.","journal-title":"Blood"},{"issue":"5663","key":"1502_CR64","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532\u20135.","journal-title":"Science"},{"issue":"3","key":"1502_CR65","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/STROKEAHA.117.019896","volume":"49","author":"C Ducroux","year":"2018","unstructured":"Ducroux C, Di Meglio L, Loyau S, Delbosc S, Boisseau W, Deschildre C, et al. Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke. Stroke. 2018;49(3):754\u20137.","journal-title":"Stroke"},{"issue":"11","key":"1502_CR66","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1161\/STROKEAHA.119.026848","volume":"50","author":"C Pena-Martinez","year":"2019","unstructured":"Pena-Martinez C, Duran-Laforet V, Garcia-Culebras A, Ostos F, Hernandez-Jimenez M, Bravo-Ferrer I, et al. Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance. Stroke. 2019;50(11):3228\u201337.","journal-title":"Stroke"},{"issue":"Supplement1","key":"1502_CR67","doi-asserted-by":"publisher","first-page":"i986","DOI":"10.1093\/esj\/aakag023.1851","volume":"11","author":"B Campbell","year":"2026","unstructured":"Campbell B, Yogendrakumar V, Churilov L, Johns H, Mutimer C, Altersberger V, et al. ABSTRACT NUMBER: ESOC2026LT15 LT15 - SAFETY AND EFFICACY OF RECOMBINANT HUMAN DNASE1 (DORNASE ALFA) AS AN ADJUVANT THROMBOLYTIC IN LARGE VESSEL ISCHAEMIC STROKE: THE EXTEND-IA DNASE CLINICAL TRIAL. Eur Stroke J. 2026;11(Supplement1):i986\u2013i.","journal-title":"Eur Stroke J"},{"issue":"10","key":"1502_CR68","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1161\/STROKEAHA.110.586289","volume":"41","author":"RG Wieberdink","year":"2010","unstructured":"Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151\u20136.","journal-title":"Stroke"},{"issue":"19","key":"1502_CR69","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood-2015-08-662650","volume":"127","author":"F Denorme","year":"2016","unstructured":"Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood. 2016;127(19):2337\u201345.","journal-title":"Blood"},{"key":"1502_CR70","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.12659\/MSM.908441","volume":"24","author":"V Prochazka","year":"2018","unstructured":"Prochazka V, Jonszta T, Czerny D, Krajca J, Roubec M, Macak J, et al. The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke. Med Sci Monit. 2018;24:3929\u201345.","journal-title":"Med Sci Monit"},{"issue":"3","key":"1502_CR71","first-page":"527","volume":"108","author":"M Crescente","year":"2012","unstructured":"Crescente M, Thomas GM, Demers M, Voorhees JR, Wong SL, Ho-Tin-Noe B, et al. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost. 2012;108(3):527\u201332.","journal-title":"Thromb Haemost"},{"issue":"11","key":"1502_CR72","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/jth.14275","volume":"16","author":"K De South","year":"2018","unstructured":"South K, Denorme F, Salles C II, De Meyer SF, Lane DA. Enhanced activity of an ADAMTS-13 variant (R568K\/F592Y\/R660K\/Y661F\/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke. J Thromb Haemost. 2018;16(11):2289\u201399.","journal-title":"J Thromb Haemost"},{"issue":"15","key":"1502_CR73","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1182\/blood-2009-03-213264","volume":"114","author":"BQ Zhao","year":"2009","unstructured":"Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329\u201334.","journal-title":"Blood"},{"key":"1502_CR74","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fneur.2019.00772","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen X, Cheng X, Zhang S, Wu D. ADAMTS13: An Emerging Target in Stroke Therapy. Front Neurol. 2019;10:772.","journal-title":"Front Neurol"},{"key":"1502_CR75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.brainres.2015.07.027","volume":"1624","author":"T Nakano","year":"2015","unstructured":"Nakano T, Irie K, Hayakawa K, Sano K, Nakamura Y, Tanaka M, et al. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication. Brain Res. 2015;1624:330\u20135.","journal-title":"Brain Res"},{"issue":"7","key":"1502_CR76","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/CIRCULATIONAHA.117.027290","volume":"136","author":"S Martinez de Lizarrondo","year":"2017","unstructured":"Martinez de Lizarrondo S, Gakuba C, Herbig BA, Repesse Y, Ali C, Denis CV, et al. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. Circulation. 2017;136(7):646\u201360.","journal-title":"Circulation"},{"issue":"2","key":"1502_CR77","doi-asserted-by":"publisher","first-page":"e0247496","DOI":"10.1371\/journal.pone.0247496","volume":"16","author":"D Kim","year":"2021","unstructured":"Kim D, Shea SM, Ku DN. Lysis of arterial thrombi by perfusion of N,N\u2019-Diacetyl-L-cystine (DiNAC). PLoS ONE [Electronic Resource]. 2021;16(2):e0247496.","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"2","key":"1502_CR78","doi-asserted-by":"publisher","first-page":"e000079","DOI":"10.1212\/WN9.0000000000000079","volume":"2","author":"S Zhang","year":"2026","unstructured":"Zhang S, Pavic NV, Maloof AG, Goh R, Priglinger M, Garcia-Esperon C, et al. N-Acetylcysteine in the Treatment of Ischemic Stroke. Neurol Open Access. 2026;2(2):e000079.","journal-title":"Neurol Open Access"},{"key":"1502_CR79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neuroscience.2025.08.006","volume":"584","author":"D Vivien","year":"2025","unstructured":"Vivien D, Lebatard S, Mazighi M, Brikci-Nigass N, Desilles JP, Tomadesso C, et al. N-acetylcysteine (NAC) as an adjunct to intravenous fibrinolysis in patients with acute ischemic stroke: a single group study (NAC-Safety). Neuroscience. 2025;584:107\u201312.","journal-title":"Neuroscience"},{"issue":"Supplement1","key":"1502_CR80","doi-asserted-by":"publisher","first-page":"i1089","DOI":"10.1093\/esj\/aakag023.2066","volume":"11","author":"S Nimjee","year":"2026","unstructured":"Nimjee S, Pavliv L, Buck R, Nelson S, Garrett G, Kienast B, et al. ABSTRACT NUMBER: ESOC2026OT73 BB-031 IN ACUTE TREATMENT: SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) IN ACUTE ISCHEMIC STROKE \u2013 THE RAISE TRIAL. Eur Stroke J. 2026;11(Supplement1):i1089\u2013i.","journal-title":"Eur Stroke J"},{"issue":"1","key":"1502_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-9560-11-2","volume":"11","author":"X Lin","year":"2013","unstructured":"Lin X, Wang Y, Zhang Y, Huang B, Lin JJ, Hallock SJ, et al. Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thromb J. 2013;11(1):2.","journal-title":"Thromb J"},{"issue":"10","key":"1502_CR82","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1182\/blood.V97.10.3086","volume":"97","author":"N Nagai","year":"2001","unstructured":"Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood. 2001;97(10):3086\u201392.","journal-title":"Blood"},{"issue":"1","key":"1502_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2040-7378-4-10","volume":"4","author":"RC Crumrine","year":"2012","unstructured":"Crumrine RC, Marder VJ, Taylor GM, LaManna JC, Tsipis CP, Novokhatny V, et al. Safety evaluation of a recombinant plasmin derivative lacking kringles 2\u20135 and rt-PA in a rat model of transient ischemic stroke. Experimental translational stroke Med. 2012;4(1):10.","journal-title":"Experimental translational stroke Med"},{"issue":"12","key":"1502_CR84","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","volume":"40","author":"VN Thijs","year":"2009","unstructured":"Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D, et al. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke. 2009;40(12):3789\u201395.","journal-title":"Stroke"},{"issue":"2","key":"1502_CR85","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.09.022","volume":"26","author":"PJ Mitchell","year":"2017","unstructured":"Mitchell PJ, Yan B, Brozman M, Ribo M, Marder V, Courtney KL, et al. Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1\/2a, Open-Label, Dose-Escalation, Safety Study. J Stroke Cerebrovasc Dis. 2017;26(2):308\u201320.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"1502_CR86","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1161\/ATVBAHA.114.304530","volume":"34","author":"GL Reed","year":"2014","unstructured":"Reed GL, Houng AK, Wang D. Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating alpha2-antiplasmin. Arterioscler Thromb Vasc Biol. 2014;34(12):2586\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1502_CR87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/biom11030347","volume":"11","author":"Z Bagoly","year":"2021","unstructured":"Bagoly Z, Barath B, Orban-Kalmandi R, Szegedi I, Bogati R, Sarkady F, et al. Incorporation of alpha2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules. 2021;11(3):25.","journal-title":"Biomolecules"},{"key":"1502_CR88","first-page":"30","volume":"30","author":"J Marta-Enguita","year":"2023","unstructured":"Marta-Enguita J, Navarro-Oviedo M, Machado F, Bermejo R, Aymerich N, Herrera M, et al. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis. J Thromb Haemostasis. 2023;30:30.","journal-title":"J Thromb Haemostasis"},{"issue":"Suppl 1","key":"1502_CR89","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jth.12216","volume":"11","author":"JH Foley","year":"2013","unstructured":"Foley JH, Kim PY, Mutch NJ, Gils A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost. 2013;11(Suppl 1):306\u201315.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1502_CR90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40261-021-01112-8","volume":"42","author":"N Sakai","year":"2022","unstructured":"Sakai N, Takeuchi M, Imamura H, Shimamura N, Yoshimura S, Naito H, et al. Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombectomy, in Japanese Patients with Acute Ischemic Stroke. Clin Drug Investig. 2022;42(2):137\u201349.","journal-title":"Clin Drug Investig"},{"issue":"Pt 2","key":"1502_CR91","doi-asserted-by":"publisher","first-page":"128618","DOI":"10.1016\/j.ijbiomac.2023.128618","volume":"257","author":"Y Xu","year":"2024","unstructured":"Xu Y, Hu Y, Wu G, Niu L, Fang C, Li Y, et al. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment. Int J Biol Macromol. 2024;257(Pt 2):128618.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1502_CR92","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41563-024-01826-y","volume":"23","author":"J Yin","year":"2024","unstructured":"Yin J, Wang S, Wang J, Zhang Y, Fan C, Chao J, et al. An intelligent DNA nanodevice for precision thrombolysis. Nat Mater. 2024;23(6):854\u201362.","journal-title":"Nat Mater"},{"issue":"6095","key":"1502_CR93","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1126\/science.1217815","volume":"337","author":"N Korin","year":"2012","unstructured":"Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science. 2012;337(6095):738\u201342.","journal-title":"Science"},{"issue":"12","key":"1502_CR94","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1161\/STROKEAHA.115.011063","volume":"46","author":"MG Marosfoi","year":"2015","unstructured":"Marosfoi MG, Korin N, Gounis MJ, Uzun O, Vedantham S, Langan ET, et al. Shear-Activated Nanoparticle Aggregates Combined With Temporary Endovascular Bypass to Treat Large Vessel Occlusion. Stroke. 2015;46(12):3507\u201313.","journal-title":"Stroke"},{"key":"1502_CR95","doi-asserted-by":"crossref","unstructured":"Prego-Dom\u00ednguez J, Laso-Garc\u00eda F, Palomar-Alonso N, P\u00e9rez-Mato M, L\u00f3pez-Arias E, Dopico-L\u00f3pez A et al. Nanoparticles for thrombolytic therapy in ischemic stroke: a systematic review and meta-analysis of preclinical studies. Pharmaceutics. 2025;17(2).","DOI":"10.3390\/pharmaceutics17020208"},{"issue":"4","key":"1502_CR96","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/bloodadvances.2021006691","volume":"7","author":"JS Palazzolo","year":"2023","unstructured":"Palazzolo JS, Ale A, Ho H, Jagdale S, Broughton BRS, Medcalf RL, et al. Platelet-targeted thrombolysis for treatment of acute ischemic stroke. Blood Adv. 2023;7(4):561\u201374.","journal-title":"Blood Adv"},{"issue":"4","key":"1502_CR97","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1474-4422(19)30026-2","volume":"18","author":"AV Alexandrov","year":"2019","unstructured":"Alexandrov AV, Kohrmann M, Soinne L, Tsivgoulis G, Barreto AD, Demchuk AM, et al. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurol. 2019;18(4):338\u201347.","journal-title":"Lancet Neurol"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-026-01502-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-026-01502-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-026-01502-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:02:14Z","timestamp":1792580534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-026-01502-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1007\/s12975-026-01502-0","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OS is the recipient of an Australian Government Research Training Program (RTP) Scholarship. No additional funds, grants or other support was received for conducting this study.","order":1,"name":"Ethics","label":"Ethical","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"111"}}